X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Preservative-free Timolol Maleate Ophthalmic Solution, USP is supplied in single-dose vials, as a sterile, isotonic, buffered, aqueous solution of timolol maleate and is indicated for treatment of elevated intraocular pressure in patients with ocular hypertension.
Lead Product(s): Timolol Maleate
Therapeutic Area: Ophthalmology Product Name: Timolol Maleate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
Under the agreement, Amring granted to Pierre Fabre an exclusive license to exploit and commercialize LYSTEDA (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB) in Mexico.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Lysteda
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pierre Fabre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
